Andre Abreu, MD, and Phillip Kuo, MD, PhD, define the standard of care and the limitations in prostate cancer imaging.
Gallium-68 PSMA Targeted PET Imaging in Prostate Cancer: Staging and Outcomes
Analysis of Gallium-68 PSMA 9 (prostate-specific membrane antigen) targeted PET (positron emission tomography) imaging and its impact on staging and prostate cancer.
The history and resultant benefits of PET (positron emission tomography) along with the utilization of PSMA (prostate-specific membrane antigen) PET imaging in treating prostate cancer is discussed.
Andre Abreu, MD, discusses the rationale behind targeting PSMA (prostate-specific membrane antigen) and its impact on the patient journey from diagnosis to biochemical recurrence.
Phillip Kuo, MD, PhD, reviews the sensitivity of PSMA (prostate-specific membrane antigen) PET (positron emission tomography) scans compared to conventional imaging.
The FDA’s approval of Ga-68 PSMA-11 and its impact on ensuring accessibility of generator versus cyclotron for new radiotracers is discussed from a nuclear medicine perspective.
Andre Abreu, MD, and Phillip Kuo, MD, PhD, on future use of PSMA targeted therapy, including insight on the phase 3 VISION trial, which used 68Ga-PSMA-11 PET/CT to identify patients for targeted treatment with 177Lu-PSMA-617.
This article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Christof Vulsteke, MD, PhD, breaks down findings, implications of KEYNOTE-905
2
The UroOnc Minute: Active Surveillance for Intermediate-risk Prostate Cancer, with Michael Leapman, MD, MHS
3
Petros Grivas, MD, on the significance of a perioperative regimen for cisplatin-ineligible MIBC
4
The Significance of KEYNOTE-905 in Muscle-Invasive Bladder Cancer
5
